Sandhya Devarajan
YOU?
Author Swipe
View article: <i>CYP2C9</i> and <i>CYP2C19</i>: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
<i>CYP2C9</i> and <i>CYP2C19</i>: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants Open
Single nucleotide variants in the open reading frames (ORFs) of pharmacogenes are important causes of interindividual variability in drug response. The functional characterization of variants of unknown significance within ORFs remains a m…
View article: Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between <i><scp>SLC</scp>38A7</i> and <i><scp>ALPPL</scp>2</i>
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between <i><span>SLC</span>38A7</i> and <i><span>ALPPL</span>2</i> Open
Anastrozole is a widely prescribed aromatase inhibitor for the therapy of estrogen receptor positive ( ER +) breast cancer. We performed a genome‐wide association study ( GWAS ) for plasma anastrozole concentrations in 687 postmenopausal w…
View article: A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) Open
Background Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose‐limiting t…